BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 23624132)

  • 1. The evolution in the use of MIBG scintigraphy in pheochromocytomas and paragangliomas.
    Rufini V; Treglia G; Perotti G; Giordano A
    Hormones (Athens); 2013; 12(1):58-68. PubMed ID: 23624132
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.
    Fottner C; Helisch A; Anlauf M; Rossmann H; Musholt TJ; Kreft A; Schadmand-Fischer S; Bartenstein P; Lackner KJ; Klöppel G; Schreckenberger M; Weber MM
    J Clin Endocrinol Metab; 2010 Jun; 95(6):2800-10. PubMed ID: 20371665
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of metaiodobenzylguanidine scintigraphy with positron emission tomography in the diagnostic work-up of pheochromocytoma and paraganglioma: a systematic review.
    Rufini V; Treglia G; Castaldi P; Perotti G; Giordano A
    Q J Nucl Med Mol Imaging; 2013 Jun; 57(2):122-33. PubMed ID: 23822989
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.
    Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Eisenhofer G; King KS; Rao JU; Wesley RA; Adams KT; Pacak K
    J Natl Cancer Inst; 2012 May; 104(9):700-8. PubMed ID: 22517990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.
    Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Havekes B; Eisenhofer G; Martiniova L; Adams KT; Pacak K
    J Clin Endocrinol Metab; 2009 Dec; 94(12):4757-67. PubMed ID: 19864450
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.
    Fiebrich HB; Brouwers AH; Kerstens MN; Pijl ME; Kema IP; de Jong JR; Jager PL; Elsinga PH; Dierckx RA; van der Wal JE; Sluiter WJ; de Vries EG; Links TP
    J Clin Endocrinol Metab; 2009 Oct; 94(10):3922-30. PubMed ID: 19622618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Superiority of 6-[18F]-fluorodopamine positron emission tomography versus [131I]-metaiodobenzylguanidine scintigraphy in the localization of metastatic pheochromocytoma.
    Ilias I; Yu J; Carrasquillo JA; Chen CC; Eisenhofer G; Whatley M; McElroy B; Pacak K
    J Clin Endocrinol Metab; 2003 Sep; 88(9):4083-7. PubMed ID: 12970267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma.
    Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Ling A; Eisenhofer G; Adams KT; Solis D; Lenders JW; Pacak K
    J Clin Oncol; 2007 Jun; 25(16):2262-9. PubMed ID: 17538171
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the performance of ⁶⁸Ga-DOTATATE PET/CT and ¹²³I-MIBG SPECT in the diagnosis and follow-up of phaeochromocytoma and paraganglioma.
    Maurice JB; Troke R; Win Z; Ramachandran R; Al-Nahhas A; Naji M; Dhillo W; Meeran K; Goldstone AP; Martin NM; Todd JF; Palazzo F; Tan T
    Eur J Nucl Med Mol Imaging; 2012 Aug; 39(8):1266-70. PubMed ID: 22526961
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic status determines
    Tiwari A; Shah N; Sarathi V; Malhotra G; Bakshi G; Prakash G; Khadilkar K; Pandit R; Lila A; Bandgar T
    J Med Imaging Radiat Oncol; 2017 Dec; 61(6):745-752. PubMed ID: 28585398
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
    van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
    J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Iodine-131 metaiodobenzylguanidine (I-131 MIBG) diagnosis and therapy of pheochromocytoma and paraganglioma: current problems, critical issues and presentation of a sample case.
    Castellani MR; Aktolun C; Buzzoni R; Seregni E; Chiesa C; Maccauro M; Aliberti GL; Vellani C; Lorenzoni A; Bombardieri E
    Q J Nucl Med Mol Imaging; 2013 Jun; 57(2):146-52. PubMed ID: 23822990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection and treatment of pheochromocytomas and paragangliomas: current standing of MIBG scintigraphy and future role of PET imaging.
    Havekes B; Lai EW; Corssmit EP; Romijn JA; Timmers HJ; Pacak K
    Q J Nucl Med Mol Imaging; 2008 Dec; 52(4):419-29. PubMed ID: 19088695
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FDG PET in the evaluation of phaeochromocytoma: a correlative study with MIBG scintigraphy and Ki-67 proliferative index.
    Lin M; Wong V; Yap J; Jin R; Leong P; Campbell P
    Clin Imaging; 2013; 37(6):1084-8. PubMed ID: 24035263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas.
    van der Harst E; de Herder WW; Bruining HA; Bonjer HJ; de Krijger RR; Lamberts SW; van de Meiracker AH; Boomsma F; Stijnen T; Krenning EP; Bosman FT; Kwekkeboom DJ
    J Clin Endocrinol Metab; 2001 Feb; 86(2):685-93. PubMed ID: 11158032
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The current status of meta-iodobenzylguanidine and related agents for the diagnosis of neuro-endocrine tumors.
    Shapiro B; Sisson JC; Shulkin BL; Gross MD; Zempel S
    Q J Nucl Med; 1995 Dec; 39(4 Suppl 1):3-8. PubMed ID: 9002740
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Usefulness of Somatostatin Receptor Scintigraphy (Tc-[HYNIC, Tyr3]-Octreotide) and 123I-Metaiodobenzylguanidine Scintigraphy in Patients with SDHx Gene-Related Pheochromocytomas and Paragangliomas Detected by Computed Tomography.
    Michałowska I; Ćwikła JB; Pęczkowska M; Furmanek MI; Buscombe JR; Michalski W; Prejbisz A; Szperl M; Malinoc A; Moczulski D; Szutkowski Z; Kawecki A; Antoniewicz J; Pęczkowski P; Lewczuk A; Otto M; Cichocki A; Bednarek-Tupikowska G; Kabat M; Janaszek-Sitkowska H; Przybyłowska K; Janas J; Neumann HP; Januszewicz A
    Neuroendocrinology; 2015; 101(4):321-30. PubMed ID: 25791839
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging of pheochromocytoma and paraganglioma.
    Brink I; Hoegerle S; Klisch J; Bley TA
    Fam Cancer; 2005; 4(1):61-8. PubMed ID: 15883712
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation dosimetry, pharmacokinetics, and safety of ultratrace Iobenguane I-131 in patients with malignant pheochromocytoma/paraganglioma or metastatic carcinoid.
    Coleman RE; Stubbs JB; Barrett JA; de la Guardia M; Lafrance N; Babich JW
    Cancer Biother Radiopharm; 2009 Aug; 24(4):469-75. PubMed ID: 19694582
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects and safety of ¹³¹I-metaiodobenzylguanidine (MIBG) radiotherapy in malignant neuroendocrine tumors: results from a multicenter observational registry.
    Yoshinaga K; Oriuchi N; Wakabayashi H; Tomiyama Y; Jinguji M; Higuchi T; Kayano D; Fukuoka M; Inaki A; Toratani A; Okamoto S; Shiga T; Ito YM; Nakajo M; Nakajo M; Kinuya S; ; ;
    Endocr J; 2014; 61(12):1171-80. PubMed ID: 25214026
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.